Data suggests avapritinib improves quality of life for patients with mastocytosis
pharmafile | June 22, 2026 | News story | Research and Development |Â Â mastocytosisÂ
New data from the PIONEER study presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026 suggest avapritinib may provide meaningful improvements in quality of life for patients with indolent systemic mastocytosis (ISM).
ISM is a rare condition driven in most cases by the KIT D816V mutation and can cause symptoms including skin rashes, gastrointestinal problems and severe allergic reactions. Many patients experience significant disruption to daily life because of the unpredictable nature of the disease.
The latest findings showed improvements across multiple measures of the Mastocytosis Quality-of-Life Questionnaire (MC-QoL), including social functioning and emotional wellbeing.
Among patients receiving avapritinib, 69.6% reported a reduction in symptom burden, while 65.8% reported fewer limitations on leisure activities. More than half also reported improvements in work or school participation and interpersonal relationships.
Patients also reported emotional benefits, including reduced fear of disease progression and fewer feelings of loneliness, concern and sadness.
In addition, 52% of participants reduced their use of symptom-directed therapies such as antihistamines and anti-IgE treatments during the study period.
According to the investigators, avapritinib remained well tolerated, with no new safety signals identified and low rates of treatment-related discontinuation.
Avapritinib is an oral tyrosine kinase inhibitor designed to target KIT receptors carrying the D816V mutation, addressing the underlying biological driver of the disease rather than focusing solely on symptom control.
The findings add to growing evidence that targeted treatment may improve both symptom burden and day-to-day functioning for people living with ISM, a condition that can have a substantial impact on social activities, work and emotional well-being.
